Bone Biologics closes $3 million private placement priced at-the-market

Bone Biologics Corporation, a Nasdaq-listed developer of orthobiologic products for spine fusion, closed a private placement on July 9, 2026. On July 7, 2026, the company priced the offering with an investor, agreeing to sell pre-funded warrants to purchase 2,112,677 shares of common stock, along with Series F warrants and Series G warrants to purchase 2,112,677 shares each, at a combined purchase price of $1.419 per pre-funded warrant and accompanying warrants.¹

The Series F warrants carry an exercise price of $1.42 per share, become exercisable once stockholders approve the issuance, and expire five years from the later of that approval date or the effectiveness of a related resale registration statement. The Series G warrants share the same $1.42 exercise price and approval-based exercisability, but expire eighteen months from the later of those two dates.¹

Net proceeds to the company were approximately $2.7 million after fees and expenses.¹ Additional gross proceeds of approximately $6 million could come to the company if the warrants are fully exercised on a cash basis.¹ The company said it intends to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and support working capital and other general corporate purposes.¹

H.C. Wainwright & Co., LLC acted as exclusive placement agent for the offering.¹ The company paid the placement agent a cash fee equal to 7.0% of gross proceeds plus a 1.0% management fee.¹ Bone Biologics also issued the placement agent warrants to purchase up to 126,761 shares of common stock, equal to 6.0% of the pre-funded warrants sold in the offering.¹

Under the purchase agreement, the company agreed to seek shareholder approval for the warrant issuance at its next annual meeting or a special meeting within 90 days of closing.¹